Abstract
The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the treatment of advanced ovarian cancer. Also, to investigate whether well-defined patient subgroups benefit more or less from cisplatin- or carboplatin-based therapy. Meta-analyses were based on updated individual patient data from all available randomized controlled trials (published and unpublished), including 37 trials, 5667 patients and 4664 deaths. The results suggest that platinum-based chemotherapy is better than non-platinum therapy, show a trend in favour of platinum combinations over single-agent platinum, and suggest that cisplatin and carboplatin are equally effective. There is no good evidence that cisplatin is more or less effective than carboplatin in any particular subgroup of patients.
Access this article
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
Similar content being viewed by others
Author information
Consortia
Rights and permissions
About this article
Cite this article
Aabo, K., Adams, M., Adnitt, P. et al. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer 78, 1479–1487 (1998). https://doi.org/10.1038/bjc.1998.710
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.710
- Springer Nature Limited
This article is cited by
-
Assessing frequency and clinical outcomes of BRCA mutated ovarian cancer in Saudi women
BMC Cancer (2022)
-
Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion
Cell Death & Disease (2022)
-
Systemische Therapie und zielgerichtete Erhaltungstherapie in der Primärsituation beim high- und low-grade Ovarialkarzinom
Der Gynäkologe (2022)
-
Inhibition of Proliferation in Ovarian Cancer Cell Line (PA-1) by the Action of Green Compound “Betanin”
Applied Biochemistry and Biotechnology (2022)
-
Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
Journal of Ovarian Research (2021)